Ignite Creation Date:
2024-05-06 @ 7:48 AM
Last Modification Date:
2024-10-26 @ 11:52 AM
Study NCT ID:
NCT02607436
Status:
COMPLETED
Last Update Posted:
2016-05-03
First Post:
2015-11-12
Brief Title:
Effect of Sarpogrelate a Serotonin Receptor Antagonist on Coronary Artery Disease
Sponsor:
Seoul National University Bundang Hospital
Organization:
Seoul National University Bundang Hospital
Study Overview
Official Title:
Effect of Sarpogrelate a Serotonin Receptor Antagonist on Progression of Coronary Artery Disease
Status:
COMPLETED
Status Verified Date:
2016-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SAGE-CAD
Brief Summary:
This is a prospective interventional study to assess the effect of sarpogrelate compared with aspirin in Korean type 2 diabetic patients with atherosclerosis
Detailed Description:
Type 2 diabetes has been increased exponentially arousing serious economic social and health repercussions Also macrovascular complications of diabetes such as myocardial infarct or stroke have been increased Individuals with diabetes have a greater risk of cardiovascular disease CVD approximately two to four times than that of those without diabetes Currently the US Food and Drug Administration requires demonstration that new anti-hyperglycemic agents do not increase cardiovascular risk The comprehensive and multifactorial management in type 2 diabetes which includes control of hypertension dyslipidemia and obesity is known to significantly reduce the risk of CVD as shown in Steno-2 study However most anti-diabetic agents currently used in clinical practice do not seem to provide enough cardiovascular protection
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None